Replies to post #827 on Revance Therapeutics Inc (RVNC)

[dewophile]

I agree in that the relative benefit of a long acting for therapeutics is more than aesthetics
all they need is POC from the cervical dystonia and I think the market will finally recognize the value of the drug. It's by no means a sure thing the ph 2 was relatively small but if that data is reproduced in ph 3 w better efficacy and duration the company will be in an extremely strong position in any licensing or buyout negotiation

[jmkobers]

I understand but do you think you will make any money if they continue to try and do it all over the next 2-3 years? My god, how much more cash will he need to do that, 400 million, 500+ based on current burn rate, PLUS go it alone cosmetic launch expenses?

I don't think there is $ to be made with that plan and neither does Mr. Market. We are getting absolutely hammered here daily because of this!

The raise @17 is beginning to make a lot more sense. The pps was ~ 20 when they announced it in Jan and you know the buyers were telling the company, "I need a major discount from where it is considering what your needs are going to be in the coming years... or I will lose big". And the next raise will be the same song, and the next, and the next....

So it comes down to how Browne decides to run the company.

Will he sacrifice share price over next several years but advance the broader pipe, or maximize share price in the short term by focusing on cosmetics and say, a single P3 for dystonia to prove POC as Dewophile suggested? And then resume large, more expansive trials across all indications after the company grows profitable.

So far it seems he is hellbent on the former.